drugset / Trial / NCT03814447
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer
Timeline
- Start
- 2019-08-16
- Primary completion
- 2023-01
- Completion
- 2023-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-MESO CAR-T cells | Cell therapy | 5e+06 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |